Private Label Wholesale CAS 1143-70-0 High Purity 98% Urolithin a Powder

• Powder: Yes
• Customized: Customized
• Certification: ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Test Method: HPLC
• MOQ: 1 Kg
• Storage: Cool Dry Place
• Sample: Avaliable
• Transport Package: 1kg Foil Bag or 25kg Drum
• Specification: 98%
• Trademark: YTBIO
• Origin: Shaanxi
• Production Capacity: 500kg/Month

Product Description

Urolithin A powder is a metabolic compound produced by gut bacteria converting ellagitannin, an inducer of mitophagy. Urolithin A switches mitochondria from CI-driven respiration to CII-driven respiration, extending lifespan and improving muscle function. It belongs to a class of organic compounds known as benzocoumarins or dibenzo-alpha-pyrone. Its precursors -- ellagic acid and ellagitannins -- are ubiquitous in nature, including edible plants like pomegranates, strawberries, raspberries, and walnuts. Urolithin A has been the subject of preliminary studies regarding its possible biological effects since the 2000s.
Ellagitannins exhibit low bioavailability and are converted to ellagic acid and its microbiota metabolites in the gut.
Urolithins are mainly present in plasma in the form of low concentrations of glucuronides.
But it also has a powerful effect, which is to improve oxidative stress, not only to scavenge free radicals, but also to inhibit oxidase enzymes, and to enhance cellular antioxidant/source.
Urolithin A can not only protect muscles, the latest research has found that urolithin A can actually affect cellular lipid metabolism and fat production.
Urolithin A has potential applications in the areas of aging, muscle health, and neurodegenerative diseases. Animal studies have shown that urolithin A supplementation can improve muscle strength and endurance and delay age-related muscle loss. In addition, urolithin A has been shown to reduce the accumulation of damaged proteins in the brain and may have potential therapeutic applications in diseases such as Alzheimer's and Parkinson's.

Further research is needed to fully understand the potential benefits and limitations of urolithin A and its mechanism of action.